| Application: | 51671, Metabolism syndrome and risk of cancer |
| Title: | Serum uric acid levels and risk of kidney cancer incidence and mortality: A prospective cohort study |
| Size: | 92795 B |
| Archived: | 31 Mar 2021 |
| Stability: | Complete |
| Personal: | No individual-level data |
Return 3266
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Notes
Objective:Epidemiological evidence investigating serum uric acid and kidney cancer risk remains unclear. We conducted this study to examine the relationship between serum uric acid and the incidence and mortality of kidney cancer.
Methods:
This is a prospective analysis of 444 462 participants without any cancer from the UK Biobank. Serum uric acid was measured at baseline and the incidence and mortality of kidney cancer was determined through contact with the cancer and death registry. Cox regression models were fitted to estimate the hazard ratio (HR) and 95% confidence interval (95%CI), adjusting for demography, lifestyle style, comorbidities, and medication use.
Results:
We documented 638 incidence cases and 188 mortality cases of kidney cancer over a median of 6.5 years follow-up. People with the highest quartile had a 45% increased risk of kidney cancer compared to those with the lowest uric acid quartile (HR 1.45, 95%CI 1.08 to 1.93). Subgroup analyses showed that serum uric acid was associated with cancer risk among females but not among males (Q1 vs Q4: females HR1.47, 95%CI 1.01 to 2.16; males HR 1.19, 95%CI 0.91 to 1.56). Although we found serum uric acid was associated with an increased risk of kidney cancer mortality in age-stratified model (HR 2.49, 95% CI 1.61 to 3.84), this association disappeared after further adjustment for other confounders.
Conclusions:
High uric acid is associated with a high incidence of kidney cancer, especially in women. More research is needed to confirm our findings.
Application 51671
Metabolism syndrome and risk of cancer
The metabolic syndrome (MetS) is a cluster of the most dangerous heart attack risk factors: diabetes and prediabetes, abdominal obesity, high cholesterol and high blood pressure. It affects around 20-25 percent of adults in the world. Previous studies have observed associations between MetS and cancer development and cancer-related deaths. However, it's still unclear which MetS components are more harmful, and whether the harmful effect are additive. For MetS and risk of certain site-specific cancer, the current evidence is still unclear. We therefore proposed this study to comprehensively evaluate MetS and cancer. We have three aims: 1. To investigate the MetS and subsequent overall and site-specific cancer risk/death 2. To investigate individual components of MetS and cancer risk/death 3. To investigate the interaction of individual components of MetS, in relation with cancer risk/ death This is a 2-year project. We will carry out a comprehensive analysis of MetS and cancer risk. The results will provide robust evidence for the management of MetS as well as the development of cancer prevention strategies.
| Lead investigator: | Dr Jin-Qiu Yuan |
| Lead institution: | Sun Yat-Sen University |
1 related Return
| Return ID | App ID | Description | Archive Date |
|---|---|---|---|
| 3265 | 51671 | Metabolic syndrome and risk of pancreatic cancer: A population-based prospective cohort study | 31 Mar 2021 |
1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 3267 | Serum uric acid levels and risk of kidney cancer incidence and mortality: A prospective cohort study | Dai XY et al. | 2020 | Cancer Med |
Enabling scientific discoveries that improve human health